The Diagnostics & Lab Testing Business Brief — Monday, November 16, 2026 cover art

The Diagnostics & Lab Testing Business Brief — Monday, November 16, 2026

The Diagnostics & Lab Testing Business Brief — Monday, November 16, 2026

Listen for free

View show details

This Season's Biggest Deal | $0.99/mo for 3 months + $20 Audible bonus

Auto-renews at $8.99/mo. after 3 months - terms apply.
Summary

The Diagnostics & Lab Testing Business Brief — Monday, November 16, 2026

  • Roche Diagnostics makes its Endotrophin (ETP) research prototype assay available on cobas e801 analyzers at Nordic Bioscience's CLIA laboratory — the second biomarker from the Roche–Nordic collaboration to reach the platform, following the CE-marked Elecsys PRO-C3. (PR Newswire)
  • Alamar Biosciences' NULISA precision proteomics platform features in 46 presentations at CTAD 2026 in Boston, including data showing brain-derived p-tau217 had the strongest association with amyloid and tau accumulation and cognitive progression among 328 plasma proteins in the A4 and LEARN studies. (GlobeNewswire)
  • Arkansas Children's Hospital laboratory develops and validates a molecular measles assay that distinguishes disease-causing from vaccine strains of the virus, presented at the AMP annual meeting in Seattle. (GenomeWeb)
  • Biovica receives a second work order, valued at approximately $150,000, under its expanded master services agreement with a leading global pharmaceutical company for DiviTum TKa testing in an oncology program, to be run at its CLIA-certified San Diego laboratory. (ACCESS Newswire)
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.